TITLE

Fighting Chance

AUTHOR(S)
Mukherjee, Siddhartha
PUB. DATE
January 2002
SOURCE
New Republic;1/21/2002, Vol. 226 Issue 2, p16
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Focuses on a talk of a biologist John Collier with a graduate student on Bacillus anthracis in the U.S. Interest of Collier on anthrax because of a peculiar property of bacteria; Information that anthrax, like a few other microbes, extrudes a deadly toxin that is capable of wreaking havoc on human cells; Report that the Pentagon and the Department of Health and Human Services have issued calls to researchers for proposals that pertain to the War on Terrorism; Information on the HIV research; Information that HIV protease closely resembles another such protease found in the human kidney-renin-which is involved in regulating blood pressure.
ACCESSION #
5890721

 

Related Articles

  • Index Case of Fatal Inhalational Anthrax Due to Bioterrorism in the United States. Bush, Larry M.; Abrams, Barry H.; Beall, Anne; Johnson, Caroline C. // New England Journal of Medicine;11/29/2001, Vol. 345 Issue 22, p1607 

    Presents the first case of inhalational anthrax to occur in the United States since 1978, important because of its origin in an act of biologic terrorism. Details of the case; Diagnosis of anthrax; Death of the patient; Discussion of Bacillus anthracis, the causative agent of anthrax.

  • Bacillus anthracis incident, Kameido, Tokyo, 1993. Takahashi, Hiroshi; Keim, Paul; Kaufmann, Arnold F.; Keys, Christine; Smith, Kimothy L.; Taniguchi, Kiyosu; Inouye, Sakae; Kurata, Takeshi // Emerging Infectious Diseases;Jan2004, Vol. 10 Issue 1, p117 

    Examines the use of an aerosol containing Bacillus anthracis in bioterrorism by the religious group Aum Shinrikyo in Kameido, Tokyo, Japan in July 1993. Details of the incident; Laboratory findings of the fluid sample from Kameido; Cases of anthrax in humans.

  • Epidemiologic Investigations of Bioterrorism-Related Anthrax, New Jersey, 2001. Greene, Carolyn M.; Reefhuis, Jennita; Tan, Christina; Fiore, Anthony E.; Goldstein, Susan; Beach, Michael J.; Redd, Stephen C.; Valiante, David; Burr, Gregory; Buehler, James; Pinner, Robert W.; Bresnitz, Eddy; Bell, Beth P. // Emerging Infectious Diseases;Oct2002, Vol. 8 Issue 10, p1048 

    Focuses on the epidemiologic investigations into bioterrorism-related anthrax in New Jersey in 2001. Extent of the anthrax outbreak in New Jersey; Assessment of the potential sources of Bacillus anthracis exposure; Contol measures being developed to prevent additional cases of anthrax.

  • Disarming anthrax. D'Epiro, Nancy Walsh // Patient Care;8/15/1998, Vol. 32 Issue 13, p18 

    Presents information on the infectious disease, anthrax, which is caused from inhalation of the spores of the bacterium, Bacillus anthracis. Harm which the disease causes to the body; Details on the findings of scientists at the National Cancer Institute.

  • Challenges of Anthrax Drug Design: In Search of “Achilles' heel” of Bacillus anthracis. Guidi-Rontani, Chantal // Letters in Drug Design & Discovery;Apr2004, Vol. 1 Issue 2, p110 

    Bacillus anthracis, the etiologic agent of anthrax, is perceived as a potential biological warfare agent. In this review, recent advances made on infection process of B. anthracis are summarized and treatment strategies are discussed.

  • Molecular Subtyping of Bacillus anthracis and the 2001 Bioterrorism-Associated Anthrax Outbreak, United States. Hoffmaster, Alex R.; Fitzgerald, Collette C.; Ribot, Efrain; Mayer, Leonard W.; Popovic, Tanja // Emerging Infectious Diseases;Oct2002, Vol. 8 Issue 10, p1111 

    Provides information on the role of molecular subtyping of Bacillus anthracis in differentiating and identifying strains during the 2001 bioterrorism-associated outbreak in the U.S. Key to developing immunity to anthrax; Multiple-locus variable-number tandem repeat analysis (MLVA) of Bacillus...

  • A dominant-negative therapy for anthrax. Leppla, Stephen H. // Nature Medicine;Jun2001, Vol. 7 Issue 6, p659 

    Focuses on the possible use of the oligomeric structure of anthrax toxin as a preventative or therapeutic vaccine. Possible use of bacterium Bacillus anthracis as a potential biological warfare; Description of proteins included in anthrax toxins.

  • Recognition and Management of Anthrax – An Update. Swartz, Morton N. // New England Journal of Medicine;11/29/2001, Vol. 345 Issue 22, p1621 

    The article explores issues related to the recognition and management of anthrax in the U.S. There had been 12 cases of clinical anthrax documented in initial reports which included two cases of inhalational anthrax among employees of a tabloid publishing company in Boca Raton, Florida. Bacillus...

  • Bacillus anthracis secretome time course under host-simulated conditions and identification of immunogenic proteins. Walz, Alexander; Mujer, Cesar V.; Connolly, Joseph P.; Alefantis, Tim; Chafin, Ryan; Dake, Clarissa; Whittington, Jessica; Kumar, Srikanta P.; Khan, Akbar S.; DelVecchio, Vito G. // Proteome Science;2007, Vol. 5, p1 

    Background: The secretion time course of Bacillus anthracis strain RA3R (pXO1+/pXO2-) during early, mid, and late log phase were investigated under conditions that simulate those encountered in the host. All of the identified proteins were analyzed by different software algorithms to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics